JP2010017185A5 - - Google Patents

Download PDF

Info

Publication number
JP2010017185A5
JP2010017185A5 JP2009192598A JP2009192598A JP2010017185A5 JP 2010017185 A5 JP2010017185 A5 JP 2010017185A5 JP 2009192598 A JP2009192598 A JP 2009192598A JP 2009192598 A JP2009192598 A JP 2009192598A JP 2010017185 A5 JP2010017185 A5 JP 2010017185A5
Authority
JP
Japan
Prior art keywords
flavivirus
virus
antigen
subviral particle
particle according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009192598A
Other languages
English (en)
Japanese (ja)
Other versions
JP5236597B2 (ja
JP2010017185A (ja
Filing date
Publication date
Priority claimed from US09/826,115 external-priority patent/US7227011B2/en
Application filed filed Critical
Publication of JP2010017185A publication Critical patent/JP2010017185A/ja
Publication of JP2010017185A5 publication Critical patent/JP2010017185A5/ja
Application granted granted Critical
Publication of JP5236597B2 publication Critical patent/JP5236597B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2009192598A 2001-04-04 2009-08-21 フラビウイルス感染症の予防のための核酸ワクチン Expired - Fee Related JP5236597B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/826,115 2001-04-04
US09/826,115 US7227011B2 (en) 1998-06-04 2001-04-04 Nucleic acid vaccines for prevention of flavivirus infection

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2002579516A Division JP4448281B2 (ja) 2001-04-04 2002-04-04 フラビウイルス感染症の予防のための核酸ワクチン

Publications (3)

Publication Number Publication Date
JP2010017185A JP2010017185A (ja) 2010-01-28
JP2010017185A5 true JP2010017185A5 (enExample) 2010-10-14
JP5236597B2 JP5236597B2 (ja) 2013-07-17

Family

ID=25245753

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002579516A Expired - Lifetime JP4448281B2 (ja) 2001-04-04 2002-04-04 フラビウイルス感染症の予防のための核酸ワクチン
JP2009192598A Expired - Fee Related JP5236597B2 (ja) 2001-04-04 2009-08-21 フラビウイルス感染症の予防のための核酸ワクチン

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2002579516A Expired - Lifetime JP4448281B2 (ja) 2001-04-04 2002-04-04 フラビウイルス感染症の予防のための核酸ワクチン

Country Status (11)

Country Link
US (6) US7227011B2 (enExample)
EP (3) EP1383931A4 (enExample)
JP (2) JP4448281B2 (enExample)
KR (1) KR100913984B1 (enExample)
CN (2) CN1304575C (enExample)
BR (1) BRPI0208301B8 (enExample)
CA (1) CA2443323C (enExample)
MX (1) MXPA03008838A (enExample)
NZ (1) NZ529106A (enExample)
WO (1) WO2002081754A1 (enExample)
ZA (1) ZA200307580B (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
EP1322655B1 (en) 2000-01-14 2007-11-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Oligodeoxynucleotide and its use to induce an immune response
US20050031641A1 (en) * 2001-04-06 2005-02-10 Loosmore Sheena May Recombinant vaccine against West Nile Virus
US7740863B2 (en) * 2001-04-06 2010-06-22 Merial Recombinant vaccine against West Nile Virus
FR2823222B1 (fr) * 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
US20040037848A1 (en) * 2001-04-06 2004-02-26 Audonnet Jean-Christophe Francis Recombinant vaccine against West Nile Virus
KR20090053967A (ko) * 2001-07-27 2009-05-28 와이어쓰 웨스트 나일 백신
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
WO2003020884A2 (en) * 2001-08-14 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method for rapid generation of mature dendritic cells
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US7351547B2 (en) * 2002-10-31 2008-04-01 Health Research, Inc. Diagnostic test for West Nile virus
US7785799B2 (en) * 2002-08-16 2010-08-31 The Board Of Regents Of The University Of Texas System Compositions and methods related to flavivirus envelope protein domain III antigens
US8263091B2 (en) * 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
JP5250179B2 (ja) 2002-11-08 2013-07-31 ザ アドミニストレイターズ オブ ザ テューレイン エデュケイショナル ファンド フラビウイルス融合インヒビター
CA2432738A1 (en) * 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
US8475808B2 (en) 2003-05-23 2013-07-02 Novartis Vaccines And Diagnostics, Inc. Immunogenic reagents from west nile virus
US7060280B2 (en) * 2003-06-11 2006-06-13 Academia Sinica Immunization against flavivirus
EP1664786B1 (en) 2003-09-09 2014-11-12 Idexx Laboratories, Inc. Detection of west nile virus infection and vaccination
US7074555B2 (en) 2004-04-28 2006-07-11 Idexx Laboratories, Inc. Detection of West Nile Virus
US20080118528A1 (en) * 2004-05-04 2008-05-22 Tsanyang Jake Liang Synthesis and Purification of West Nile Virus Virus-Like Particles
CN103088038B (zh) * 2004-07-12 2015-06-24 美国天甲生物医药有限公司 黄病毒疫苗
ATE521627T1 (de) 2004-07-27 2011-09-15 Us Gov Health & Human Serv Identifikation kreuzreaktiver epitope des flavivirus-hüllglykoproteins
WO2006029300A2 (en) * 2004-09-09 2006-03-16 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
JP4993301B2 (ja) * 2004-10-20 2012-08-08 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー 日本脳炎ウイルスおよび西ナイルウイルスに対するワクチン
AU2006232865A1 (en) * 2005-04-01 2006-10-12 Wyeth Use of WNV DNA vaccine in combination with a conventional vaccine to overcome immunogen interference
KR102017842B1 (ko) 2005-04-08 2019-09-03 와이어쓰 엘엘씨 다가 폐렴구균 다당류-단백질 접합체 조성물
EP1896069B1 (en) * 2005-06-24 2013-03-13 Intervet International BV Inactivated chimeric vaccines and related methods of use
US7455842B2 (en) * 2005-12-05 2008-11-25 University Of Kansas Chimeric West Nile viruses and uses thereof
US20070190617A1 (en) * 2006-02-13 2007-08-16 Chang-Jer Wu DNA vaccine for Japanese encephalitis virus
US20080044808A1 (en) * 2006-08-15 2008-02-21 Qian-Li Song West nile virus antigen and assay
EP2086526B1 (en) * 2006-11-09 2014-07-23 The United States Of America As Represented By The Secretary of the Navy Induction of an immune response against Dengue virus using prime-boost approach
SI2308514T1 (sl) 2007-03-23 2013-09-30 To-Bbb Holding B.V. Konjugati za prenos zdravila preko krvno-moĹľganske pregrade
JP2008263964A (ja) * 2007-03-29 2008-11-06 Yamaguchi Univ コウモリ由来細胞株
EP2003144A1 (en) * 2007-06-15 2008-12-17 Institut Pasteur Method for the diagnosis or the screening of an arbovirus infection, reagents useful in said method and their applications
WO2009024534A2 (en) * 2007-08-17 2009-02-26 Intercell Ag Japanese encephalitis virus (jev) and tick-borne encephalitis virus (tbev) peptides stimulating human t cell responses
US8138318B2 (en) * 2007-09-13 2012-03-20 Abbott Laboratories Hepatitis B pre-S2 nucleic acid
KR101686942B1 (ko) * 2008-01-11 2016-12-28 이노비오 파마수티컬즈, 인크. 뎅기 바이러스 다중 서브타입에 대항하는 신규한 백신
WO2009098277A1 (en) * 2008-02-08 2009-08-13 Intercell Ag Flaviviridae mutants comprising a deletion in the capsid protein for use as vaccines
MX2010011373A (es) * 2008-04-22 2010-11-12 Cytos Biotechnology Ag Composiciones de vacuna para el tratamiento de la fiebre del dengue y uso de las mismas.
CN101333246B (zh) * 2008-07-30 2011-04-13 中国农业科学院哈尔滨兽医研究所 乙型脑炎病毒e蛋白中和性b细胞抗原表位多肽及其应用
MX2011002071A (es) 2008-08-29 2011-04-05 Boehringer Ingelheim Vetmed Vacuna para el virus del nilo occidental.
CN101607983B (zh) * 2009-07-29 2012-06-13 中国农业科学院哈尔滨兽医研究所 乙型脑炎病毒PrM/M蛋白B细胞抗原表位多肽及应用
ES2524975T3 (es) 2009-07-31 2014-12-16 Ge Healthcare Bio-Sciences Corp. Cepa del virus de la fiebre amarilla de alto rendimiento con mayor propagación en células
US20110182976A1 (en) * 2010-01-28 2011-07-28 National Taiwan Ocean University Lipoplex-patch based dna vaccine
CN102906266A (zh) 2010-05-21 2013-01-30 高等教育联邦系统-匹兹堡大学 登革病毒通用序列及其使用方法
AR079970A1 (es) * 2010-07-23 2012-02-29 Xcellerex Inc Cepas de alto rendimiento del virus de la fiebre amarilla con una propagacion incrementada en las celulas
WO2012065105A2 (en) * 2010-11-12 2012-05-18 Thomas Monath Chimeric flavivirus vaccines
EP2772266B1 (en) 2011-03-14 2019-07-31 Boehringer Ingelheim Animal Health USA Inc. Equine Rhinitis vaccine
EP3269728B1 (en) 2011-10-20 2020-12-16 The Government of The United States of America as represented by The Secretary, Department of Health and Human Services Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes
US8920804B2 (en) 2011-12-22 2014-12-30 Inbios International, Inc. Methods and materials for the detection of dengue virus infection
US20150265695A1 (en) * 2012-07-24 2015-09-24 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
EP3031923A1 (en) * 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
CN104630160B (zh) * 2015-01-23 2018-04-27 中国农业科学院哈尔滨兽医研究所 表达西尼罗热病毒PrM/E蛋白的重组新城疫LaSota疫苗株
EP3316905A1 (en) 2015-07-03 2018-05-09 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
US11007260B2 (en) * 2015-07-21 2021-05-18 Modernatx, Inc. Infectious disease vaccines
US10947277B2 (en) 2016-06-13 2021-03-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nucleic acids encoding zika virus-like particles and their use in zika virus vaccines and diagnostic assays
US20180028643A1 (en) * 2016-06-21 2018-02-01 Brock Adam Kingstad-Bakke Zika virus vaccines using virus-like particles
US10898566B2 (en) 2016-09-19 2021-01-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Zika virus vaccines
EP4043031A3 (en) * 2016-11-17 2022-11-23 GlaxoSmithKline Biologicals SA Zika viral antigen constructs
WO2018152526A1 (en) 2017-02-20 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Zika virus vaccines
US11690903B2 (en) 2017-10-05 2023-07-04 Sanofi Pasteur Compositions for booster vaccination against dengue
WO2019162454A1 (en) * 2018-02-22 2019-08-29 Euroimmun Medizinische Labordiagnostika Ag Assay for the diagnosis of viral infections
EP3530668A1 (en) * 2018-02-22 2019-08-28 Euroimmun Medizinische Labordiagnostika AG A novel assay for the diagnosis of viral infections
CN113372441B (zh) * 2018-04-04 2023-03-10 中国科学院微生物研究所 一种高灵敏度的黄热病毒人源单克隆抗体及其应用
CN108904793B (zh) * 2018-07-29 2021-03-30 首都医科大学附属北京友谊医院 预防流行性乙型脑炎的dna疫苗及其构建方法
CA3124373A1 (en) * 2018-12-20 2020-06-25 The Wistar Institute Of Anatomy And Biology Vaccines against powassan virus, and methods of using same
US20250276051A1 (en) * 2019-12-18 2025-09-04 Geneone Life Science, Inc. Powassan viral antigens and related compositions, and uses thereof to vaccinate and treat patients
KR102216078B1 (ko) * 2020-04-22 2021-02-16 국방과학연구소 유전자 백신으로 사용하기 위한 항원 유전자 전달용 발현 벡터 및 이를 포함하는 유전자 백신
WO2021262659A1 (en) * 2020-06-22 2021-12-30 University Of Connecticut Flavivirus signal peptides, vaccine constructs, and methods therefor
WO2024097725A1 (en) * 2022-11-02 2024-05-10 Takeda Vaccines, Inc. A method for determining the infectivity of a virus

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (enExample) 1968-10-17 1970-08-24
JPS53133627A (en) 1977-04-25 1978-11-21 Nippon Seibutsu Kagaku Kenkiyu High purity deactivated vaccine for japanese encephalitis
JPH0768267B2 (ja) * 1986-06-05 1995-07-26 財団法人阪大微生物病研究会 フラビウイルス抗原
JPS634895A (ja) 1986-06-24 1988-01-09 Mitsubishi Electric Corp オゾン精製水供給装置
JPS63105682A (ja) 1986-10-23 1988-05-10 Mitsubishi Kasei Corp デングウイルス3型由来のcDNA
FR2614219B1 (fr) 1987-04-23 1993-07-09 Materiels Annexes Dialyse Procede de fabrication de granules destines a la preparation de solutions de dialyse et installation pour sa mise en oeuvre.
JPH084508B2 (ja) 1987-09-16 1996-01-24 国立予防衛生研究所長 組み換えワクチニアウイルス
US4783502A (en) 1987-12-03 1988-11-08 Ppg Industries, Inc. Stable nonaqueous polyurethane microparticle dispersion
JP2511494B2 (ja) 1988-05-12 1996-06-26 善治 松浦 日本脳炎ウイルス表面抗原蛋白質の製造法
IL91304A0 (en) 1988-08-20 1990-03-19 Us Health Recombinant vaccinia virus for prevention of disease caused by flavivirus
JPH0425408A (ja) 1990-05-21 1992-01-29 Hitachi Ltd ペレタイジングシステムの自動連続運転制御方法
FR2665710A1 (fr) 1990-08-10 1992-02-14 Pasteur Institut Baculovirus recombinant exprimant les proteines e et ns1 de virus appartenant aux flaviviridae ou de virus apparentes aux flaviviridae, applications diagnostiques et therapeutiques.
US5514375A (en) 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5494671A (en) 1990-08-27 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2140418T3 (es) * 1991-09-19 2000-03-01 Us Health Flavivirus quimericos y/o flavivirus de crecimiento restringido.
JPH05276941A (ja) 1992-02-28 1993-10-26 Nippon Zeon Co Ltd フラビウイルス科に属するウイルスの表面抗原タンパク質を含む非感染性の構造物粒子の製造方法
JPH07265093A (ja) 1994-03-30 1995-10-17 Chemo Sero Therapeut Res Inst 哺乳動物細胞を用いる日本脳炎ウイルス表面抗原蛋白質の製法
US6136561A (en) * 1995-05-24 2000-10-24 Hawaii Biotechnology Group, Inc. Methods of preparing carboxy-terminally truncated recombinant flavivirus envelope glycoproteins employing drosophila melanogaster expression systems
ATE227584T1 (de) 1995-05-24 2002-11-15 Hawaii Biotech Group Untereinheitsimpfstoff gegen flavivirus infektion
US6074865A (en) * 1995-07-20 2000-06-13 The United States Of America As Represented By The Secretary Of The Army Recombinant dengue virus DNA fragment
US6455509B1 (en) * 1996-06-04 2002-09-24 The United States Of America As Represented By The Secretary Of The Navy Dengue nucleic acid vaccines that induce neutralizing antibodies
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
DE69830579T2 (de) * 1997-02-28 2006-05-04 Acambis, Inc., Cambridge Chimäre impfstoffe gegen flaviviren
EP1005363B1 (en) 1997-07-31 2006-03-29 Hawaii Biotech, Inc. Recombinant dimeric envelope vaccine against flaviviral infection
EP1047448B1 (en) 1997-11-20 2006-02-01 United States Army Medical Research and Materiel Command Dna vaccines against tick-borne flaviviruses
IL139844A0 (en) 1998-06-04 2002-02-10 Us Gov Health & Human Serv Nucleic acid vaccines for prevention of flavivirus infection
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
WO2002083903A2 (en) 2001-02-28 2002-10-24 Brown University Research Foundation West nile virus epitopes and uses thereof
AU2002309508A1 (en) 2001-03-12 2002-09-24 L2 Diagnostics, Llc Compositions and methods comprising west nile virus polypeptides

Similar Documents

Publication Publication Date Title
JP2010017185A5 (enExample)
Martinez-Flores et al. SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants
Yong et al. Recent advances in the vaccine development against Middle East respiratory syndrome-coronavirus
US11826416B2 (en) Induce and enhance immune responses using recombinant replicon systems
Boyoglu-Barnum et al. Biology of infection and disease pathogenesis to guide RSV vaccine development
JP6797275B2 (ja) フラビウイルスワクチン接種のための組成物及び方法
JP2004532023A5 (enExample)
JP2016501015A5 (ja) デングウイルス血清型4(den−4)構築物に関する組成物、方法および使用
JP2008529558A5 (enExample)
JP2008508859A5 (enExample)
JP2013542224A5 (enExample)
JP2019151636A5 (enExample)
JP2010522540A5 (enExample)
JP2015524422A5 (enExample)
HUP0002139A2 (hu) Kiméra flavivírus-vakcinák
FI3539565T3 (fi) Koostumuksia ja menetelmiä dengue-viruksen kimeerisille rakenteille rokotteissa
JP2014529399A5 (enExample)
JP2014513952A5 (enExample)
JP2009504654A5 (enExample)
WO2004085633A8 (en) A novel human virus causing severe acute respiratory syndrome (sars) and uses thereof
JP2019511221A (ja) 弱毒化された生ジカウイルスワクチン
JP2016504315A5 (enExample)
JP2005510244A5 (enExample)
ES2637629T3 (es) Inducción de una respuesta inmunitaria frente al virus del dengue usando un enfoque de sensibilización-refuerzo
JP2019535291A5 (enExample)